Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.

@article{GonzlezLpez2017UseOE,
  title={Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.},
  author={Tom{\'a}s J Gonz{\'a}lez-L{\'o}pez and Mar{\'i}a Teresa {\'A}lvarez-Rom{\'a}n and Cristina Y. Pascual and Blanca S{\'a}nchez-Gonz{\'a}lez and Fernando Fern{\'a}ndez-Fuentes and Gloria P{\'e}rez-Rus and Jos{\'e} {\'A}ngel Hern{\'a}ndez-Rivas and Silvia Bernat and Jose Mar{\'i}a Bastida and Mar{\'i}a Paz Mart{\'i}nez-Badas and Violeta Mart{\'i}nez-Robles and I Soto and Pavel E Olivera and Estefan{\'i}a Bola{\~n}os and Rafael Alonso and Laura Entrena and Marta G{\'o}mez-N{\'u}{\~n}ez and Arancha Alonso and Mar{\'i}a Yera Cobo and Isabel S Caparr{\'o}s and Mar{\'i}a Teresa Tenorio and Esther Arrieta-Cerd{\'a}n and Elsa L{\'o}pez-Ansoar and Javier Garc{\'i}a-Frade and J R Gonzalez-Porras},
  journal={British journal of haematology},
  year={2017},
  volume={178 6},
  pages={
          959-970
        }
}
Eltrombopag is a second-line treatment in primary immune thrombocytopenia (ITP). However, its role in secondary ITP is unknown. We evaluated the efficacy and safety of eltrombopag in secondary ITP in daily clinical practice. Eighty-seven secondary ITP patients (46 with ITP secondary to autoimmune syndromes, 23 with ITP secondary to a neoplastic disease subtype: lymphoproliferative disorders [LPDs] and 18 with ITP secondary to viral infections) who had been treated with eltrombopag were… CONTINUE READING
3
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES